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Abstract 
Neuropharmacology is a very crucial field of science that encompasses many aspects of the 
nervous system from mono neuron manipulation to throughout brain, spinal cord, and 
peripheral nerves. To know the basis of drug development, one must first understand how 
neurons communicate between one another. In recent years, extremely successful progress 
has been made by the pharmaceutical industry on a number of disease fronts; however, the 
progress made in the treatment of CNS disorders has lagged behind. Although several major 
advancements in neurobiology have been made in the past few decades, the complicated 
chemical reactions driving human consciousness are still poorly understood. Diseases of the 
CNS are also substantially more complicated than other diseases. These disease states, 
including depression, epilepsy, neurodegenerative disorders, neuropathic pain, multiple 
sclerosis (MS) and schizophrenia are complicated disorders affecting mood, memoryand 
mobility: the true essence of being.Neuropharmacology is understanding the actions of drugs 
on the functions of the brain, whether it be on single cells or behavior, is a multilevel, 
multifaceted process that begins with andbuilds upon the concept of molecular interactions. 
Furthermore, it is   concerned with drug induced changes in the functioning of cells in the 
nervous system. 
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INTRODUCTION 
Neuropharmacology, upto the 20th 
century, did not appear in scientific 
research, scientists were able to figure out 
a basic understanding of the nervous 
system and how nerves communicate each 
other. However, prior to this discovery, 
some medicines were demonstrated with 
some type of influence on the nervous 
system. French scientists start working on 
a compound i.e., phenothiazine in the 
1930’s, in expectation of a new compound 
to combat malaria. Though the expectation 
was found very little of drug’s effect in the 
use against malaria infected individuals, it 
was found to have sedative effects along 
with what appeared to be beneficial effects 
toward patients with Parkinson’s disease. 
this black method to investigate a drug 
without mechanism was the main approach 
to this field, while in between the late 1940 
and early 1950, scientists were 
scientifically able to identify specific 
neurotransmitters i.e., norepinephrine 
(constriction of blood vessels and the 
increase in heart rate and blood pressure), 
dopamine (the chemical whose shortage is 
involved in Parkinson’s disease), and 5-
Hydroxytryptamine (5-HT). In the 1950s, 
scientists also became better able to 
measure levels of specific neurochemicals 
in the body and thus correlate these levels 
with behavior [1]. Neuropharmacology 
deals with the cellular function in the 
nervous system. Neuropharmacology is 
divided in two branches i.e., molecular 
(neurochemical interactions) and 
behavioral (neuropsychopharmacology) 
[2] with the overall goal of developing 
drugs that have beneficial effects on 
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neurological function. Both of these 
branches are very close to each other, 
since both are linked with communications 
of neurotransmitters, neuropeptides, 
neuromodulators, second messengers, 
neurohormones, enzymes, ion channels, 
co-transporters, and receptor proteins in 
the peripheral and central nervous system. 
On the basis of these interactions 
researchers are developing new chemical 
moieties and drugs to treat various 
neurological disorders, including pain, 
neurodegenerative diseases such as 
Parkinson's disease and Alzheimer's 
disease, psychological disorders, 
addiction, and many others. 
 
 
Figure 1: Organization of human brain. 
 
Neuropsychpharmacology is an all-
encompassing term that typically is 
applied to all types of drug effects that 
influence nervous system functioning. The 
term psychopharmacology is often used to 
describe the effect of drugs on 
psychological parameters such as emotions 
and cognition. Drugs that influence 
behaviour are known as psychotropic 
agents. In our study we have used the term 
neuropharmacology to describe the study 
of all drugs that have effect on the nervous 
system, whether they affect sensory 
perception, motor function, seizure 
activity, mood, higher cognitive function 
or other forms of nervous system 
functioning. 
 
Fundamental key concepts 
 An understanding of drug action in the 
brain must integrate knowledge of 
molecular and cellular actions of a 
drug with their effects on the brain. 
 The drug can be classified as agonists, 
partial agonists, inverse agonists, 
partial inverse agonist, or antagonists. 
 The clinical actions of drug in the brain 
are often due to neural plasticity – long 
term adaptations of neurons to the 
sustained short term actions of drug. 
 The binding of a drug to its specific 
target(s) normally is saturable and 
stereo selective. 
 The binding of a drug to its specific 
target is quantified according to its 
affinity for the target. 
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 Potency of drug describes the strength 
of binding between drug and its target, 
efficacy describes the maximal 
biologic effect that the drug exerts by 
binding to its target. 
 Modern neuropharmacology takes the 
advantage of the tools of molecular 
biology, genetics and cell biology 
combinatorial chemistry which is used 
to generate novel molecules that may 
function as new drugs. 
 
Basic principles of Neuropharmacology: 
[3]
 
Most pharmacological manipulations 
relevant to psychopharmacology target 
synaptic activity or physiological 
processes directly related to synaptic 
activity. Until recently the only notable 
exceptions to this principle were the local 
anesthetics and perhaps the antimanic 
compound lithium chloride. During the 
past decade progress in understanding the 
neurochemistry of second-messenger 
systems has afforded a new target for 
pharmacological manipulation that has 
already enjoyed wide-spread popularity. 
 
Localization of Receptors: 
Postsynaptic receptors (interneuronal 
communication)  
 Dendritic  
 Somatic  
 Axonal  
 Neuroeffector (nonneuronal target 
tissues)  
 
Autoreceptors (intraneuronal feedback)  
 Presynaptic  
 Dendritic  
 Somatic  
 
Types of Synaptic Connections 
 Neuromuscular junction  
 Axodendritic synapse  
 Axosomatic synapse  
 Axoaxonic synapse  
 Dendrodendritic "synapse"  
 
Synaptic Dynamics: 
Neurotransmitter synthesis and storage  
 Substrate availability  
 Feedback inhibition  
 Enzyme induction  
 Action potential  
 Impulse-coupled release of 
neurotransmitter (Ca++ dependent)  
 Diffusion across synaptic cleft to 
postsynaptic receptor  
 Binding to postsynaptic receptor 
(affinity)  
 Activity at postsynaptic receptor 
(efficacy)  
 Fast-acting neurotransmitters 
 Excitatory (depolarization by opening 
Na
+
 channels)  
 Inhibitory (hyperpolarization by 
opening K
+
 or Cl
-
 channels)  
 Slow-acting 
neurotransmitters/neuromodulators 
 Deactivation  
 Diffusion (trivial influence in CNS)  
 Reuptake (primary mechanism for 
biogenic amines)  
 Enzymatic degradation (primary 
mechanism for acetylcholine)  
Signal Transduction: 
Signal-transduction mechanisms can be 
divided into two general types, depending 
on the relationship of the transducer and 
effector mechanisms and the relative 
importance of intracellular mechanisms for 
producing the biological response. Two 
receptors are involved in interaction of 
neurotransmitters on post synaptic neuron. 
The first types of receptors are ligand-
gated ion channels or LGIC’s are the 
fastest types of transduction from chemical 
signal to electrical signal. A receptor binds 
with neurotransmitter as well the 
conformational change allows the ions to 
flow into the cell. Other receptor is known 
as G-protein-coupled receptors or GPCR’s 
which are much slower than LGIC’s due to 
an increase in the amount of biochemical 
reactions that must take place intracellular. 
When the neurotransmitter binds to GPCR 
protein, the intracellular interactions leads 
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to various changes in cellular response 
gene expression [4]. 
 
 
Ligand gated ion channels 
Ligand gated ion channel (LGIC) receptors 
are the fastest types of transduction from 
chemical signal to electrical signal. 
 
 
Figure 2: Model of a ligand-gated receptor mechanism. 
 
Second-messenger systems 
These are slower-acting mechanisms 
(although still sometimes relatively fast) 
that can produce a myriad of complex 
effects following neurotransmitter 
activation. These effects range from 
opening ion channels (similar to that seen 
in ligand-gated ion channels) to 
stimulating or inhibiting neurotransmitter 
synthesis (Fig.3). Second-messenger signal 
transduction always involves intracellular 
processes, even when the end result is a 
change in membrane conductance. A 
presynaptic neurotransmitter activates 
adenylatecyclase, which converts ATP to 
cAMP, giving off inorganic phosphates 
(PPi) as a byproduct. cAMP activates a 
protein kinase, which phosphorylates a 
receptor protein in the postsynaptic 
membrane.Phosphate addition alters the 
conformation of the receptor protein and 
allows increased ion conductance through the 
membrane.The ion conductance can result in 
either depolarization or hyperpolarization of 
the membrane. Membrane phosphorylation is 
reversed by the enzyme phosphoprotein 
phosphatase and cAMP is deactivated by 
phosphodiesterase. A presynaptic receptor 
also utilizes cAMP to inhibit transmitter 
synthesis.
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Figure 3: Second-messenger mediated synaptic transmission. 
 
Neurons classified as using second-
messenger systems are viewed as 
performing signal transduction in two 
stages: neurotransmitter receptor-binding 
(first-messenger process) produces a 
cascade of neurochemical events (second-
messenger process; e.g., cAMP formation) 
that leads to changes in the target-cell 
activity (e.g., opening ion channels, 
increased protein synthesis).  
 
Principles of Cellular Excitability and 
electrochemical Transmission: [5] 
Cellular communication is essential for the 
effective functioning of any complex 
multicellular organism. The major mode of 
intercellular communication is the 
transmission of chemical signals, such as 
neurotransmitters and hormones. In 
excitable tissues, such as nerves and 
muscles, rapid intracellular 
communication relies on the propagation 
of electrical signals- action potentials- 
along the plasma membrane of the cell. 
Both chemical and electrical transmissions 
commonly involve the movements of ions 
across the plasma membranes of internal 
organelles such as the endoplasmic 
reticulum or mitochondria. Ionic 
movements can directly change the 
cytoplasmic concentration of ions, such as 
the Ca
2+
 that are key regulators of 
biochemical and physiological processes 
such as phosphorylation, secretion and 
contraction. Ionic movements also change 
the electrical potential across the 
membrane through which the ions flow, 
thus regulating various voltage-dependent 
functions, such as the opening of other ion 
channels. Some of these events are brief 
with durations and actions of several 
milliseconds (0.001 sec). Others can take 
many seconds, with biochemical 
consequences that can persist for minutes 
or hours. The fundamental basis for 
cellular excitability lies in the 
electrochemical gradients that are 
established by ion pump across the lipid 
bi-layer of the plasma membrane. Ion-
selective channels enable cellular 
membranes to regulate selectively the 
permeability of the membrane to different 
ionic species, allowing a change in 
membrane voltage to be coupled to a 
chemical stimulus or response. The action 
potential, a special type of stereotyped 
response found in excitable cells, is made 
possible by the voltage dependent 
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properties of Na
+
 and K
+
 channels. The 
basic process of electrochemical 
transmission provides the substrate for 
pharmacologic modulation of cellular 
excitation and communication. 
 
CNS Disorders 
CNS disorders were first recorded in 
cultures as far back as antiquity and thus 
have long troubled society. CNS disorders 
are complex illnesses that continue to 
represent a major challenge to neurology 
and psychiatry. 
 
CNS disorders are treated by targeting 
symptoms 
The origin of current drug therapy used to 
alleviate the symptoms of CNS disorders 
was developed in the 1950s, in many 
cases, quite serendipitously (Fig. 2). For 
example, the early typical antipsychotic, 
chlorpromazine, was synthesized in 1949 
as an agent to potentiate anaesthesia before 
being recognised in 1951 for its value in 
the treatment of schizophrenia [6]. The 
hypothesis that schizophrenia may 
represent hyperfunction of dopaminergic 
signaling was proposed, in part, after 
chlorpromazine and other phenothiazines 
were shown to act as D2 receptor 
antagonists [7,8]. From then on, the 
possibility that neurochemical disturbances 
may underlie the cause of many CNS 
disorders began in earnest. In Alzheimer’s 
disease, a striking loss in neurotransmitter 
content, particularly for acetylcholine, was 
shown to parallel neuronal loss associated 
with the onset of dementia. With the 
observation that central cholinergic 
antagonists precipitate confusion 
reminiscent of dementia attention was 
focused on agents that would mimic or 
enhance the actions of acetylcholine [9]. 
Although newer compounds have been 
developed to treat CNS disorders in the 
last five decades, in almost all cases, the 
overall strategy has been to treat the 
symptoms whilst offering the patient a 
drug regime with as few side-effects as 
possible. Many drugs however are 
completely ineffective or exhibit 
appreciable side-effects accounting for 
poor drug compliance amongst many 
patients [10, 11]. To achieve the 
substantial improvement in the treatment 
of CNS illness, two factors need to be 
considered: firstly identification of the 
underlying mechanism of the CNS defects 
and, secondary Selective drug delivery to 
limit potential side-effects. 
 
 
Figure 4:  CNS disorders are treated by targeting the symptoms 
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A list of most of the major CNS disorders 
that afflict society and the drugs 
commonly used totreat them. Despite 
advances in our understanding of the CNS, 
most conditions are treated byattempting 
to alleviate symptoms rather than tackling 
the root cause of the disease. 
 
EPILEPSY 
Epilepsy is a significant health problem. 
there are numerous examples of ineffective 
mono or poly therapy, while a number of 
ion channels, amino acids and/or receptors 
are targeted by older   and newer 
pharmacologically active agents. Seizures 
that are secondary to CNS infections are 
among the most refractory medically, and 
thus insult-specific agents are desirable.  
 
Epilepsy is a neurological disease 
associated by connate recurrence of 
uncaused seizures. It is not accurate to 
refer to seizures as epilepsy, although 
“seizure disorder” refers to epilepsy [12]. 
 
Seizures are time-limited paroxysmal 
events that result from abnormal, 
involuntary, rhythmic neuronal discharges 
in the brain. Except for rare instances of 
reflex epilepsy, seizures are not predictable 
and can occur at inconvenient, 
embarrassing or even dangerous 
times.This unpredictability is the most 
distressing aspect of epilepsy forms any   
patients. Seizures are involuntary events 
and patients usually cannot control their 
onset or termination which further adds to 
frustration. Seizures are usually short, 
lasting less than 5 minutes, but can be 
preceded by a prodromal phase and 
followed by a long postictal phase, during 
which there is gradual return to baseline 
[12]. 
 
Epilepsy is a significant public health 
problem, and the newest drugs and 
neurosurgical advances are unable to 
provide a cure for the disease. The cellular 
and neuro circuit bases of epilepsy are 
poorly understood, and 20–25% of patients 
respond poorly to existing medications. 
Increasing experimental evidence during 
the past 25 years has demonstrated a role 
for dynorphin in temporal lobe epilepsy. In 
an effort to match diagnoses and treatment 
of problematic or challenging cases of 
epilepsy during the same period, the 
International League against Epilepsy has 
proposed a new system of classification 
based on the following criteria: (i) 
descriptive (ii) pathophysiological (iii) 
syndrome (iv) etiology and (v) functional 
disability [13]. 
 
Epilepsy is a very common disorder, 
characterized by ‘seizures’, which take 
various form of the seizure depending on 
the part of the brain affected. Epilepsy 
affects 0.5- 1% of the population. Often 
there is no recognizable cause, although it 
may develop after brain damage, such as 
trauma, infection or tumor growth or other 
kinds of neurological syndromes. 
 
Factors that define epilepsy syndromes: 
[12] 
 Seizure type 
 Age at onset of seizure 
 Family history 
 Physical examination 
 EEG (ictal and interictal) 
 Neurologic imaging studies 
 
The epilepsies are common and frequently 
devastating disorders, affecting 
approximately 2.5 million people in the 
United States alone. Approximately 40 
different forms and six major types of 
epilepsy have been identified. Loss of 
transient impairment seizures often cause 
transient impairment of consciousness, 
results in risk of bodily harm and often 
interfering with education and 
employment [14].
 
 
Vocabulary of Epilepsy 
The main event of epilepsy is seizure. The 
causes of seizures are many and include 
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the full range of neurologic diseases, from 
infection to neoplasm and head injury. In 
some subgroups, heredity has proved to be 
a major contributing factor [15]. 
 
Seizures are time-limited paroxysmal 
events that result from abnormal, 
involuntary, rhythmic neuronal discharges 
in the brain. Except for rare instances of 
reflex epilepsy, seizures are not predictable 
and can occur at inconvenient, 
embarrassing or even dangerous times. 
Whether any of these prevent the 
development of epilepsy (epileptogenesis) 
is uncertain [16]. 
 
Types of Epilepsy: [14] 
There are two major categories of seizures: 
1. Partial seizure 
2. Generalized seizure 
3. Either form is classified as simple (if 
consciousness is not lost) or complex 
(if consciousness is lost). 
 
Partial seizures 
Partial seizures are those in which the 
discharge begin locally and often remains 
localized. The symptoms depend on the 
brain region or region involved and includes 
involuntary muscle contractions, abnormal 
sensory experiences or autonomic discharge 
or effects on mood and behavior often 
termed psychomotor epilepsy. An epileptic 
focus in the motor cortex results in attacks, 
sometimes called Jacksonian epilepsy, 
consisting of repetitive jerking of a 
particular muscle group which spreads and 
may involve much of the body within 2 
minutes before dying out. In psychomotor 
epilepsy, which is often associated with a 
focus in the temporal lobe, the attack may 
consist of stereotyped purposive movements 
such as rubbing or patting movements or 
much more complex behavior such as 
dressing or walking or hair- combing. 
Complex partial seizures are among the 
commonest type of epilepsy. 
Generalised Seizures 
Involvement of brain and reticular system 
in the generalized seizures produces 
abnormal electrical activity in both 
hemispheres. Immediate loss of 
consciousness is characteristic of 
generalised seizures. Two important 
categories are- tonic-clonic seizure (grand 
mal) and absence seizures (petit mal). 
Strong contraction of musculature causes 
rigid extensor spasm, stops respiration, 
frequency of urine and saliva secretion 
takes place often. Aggression and 
concomitant jerks lasts upto 2-4 minutes 
from results of one minute duration tonic 
phase. Patient losses their consciousness 
for more some minutes and then recovers. 
Convulsive phase may cause injury. 
 
The less dramatic and more frequent 
(repeated seizures each day) phase is 
absence seizures in children, compare to 
tonic- clonic seizures. 
 
Status epilepticus: [17] 
Status epilepticus is a life- threatening 
condition in which seizure activity is 
uninterrupted. Status epilepticus is defined 
as epileptic activity that continues for over 
30 min, either as a single seizure or as 
recurrent seizures without inter-ictal return 
of consciousness. The probability of 
neuronal damage is proportional to the 
seizure duration and the overall mortality 
rate is about 20%. The occurrence of non-
convulsive status epilepticus in critically 
ill neurosurgical patients is being 
increasingly recognized with reported 
incidences of 8–34%. Status epilepticus is 
a comparatively rare admission diagnosis 
(<1%) in patients admitted to an intensive 
care unit (ICU). However, at least 10% of 
patients admitted to an ICU with a primary 
non-neurological diagnosis experience 
neurological complications, of which the 
second most common are seizures or status 
epilepticus.
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Classification and aetiology of status epilepticus: [18, 19]
 
Table 1: Clinical classification of SE.
 
 
Table 2: Aetiology of status epilepticus. 
 
 Chronic epilepsy ± subtherapeutic antiepileptic drug levels 
 Profound biochemical imbalance (sodium,calcium,uraemia) 
 Stroke 
 Chronic alcohol ingestion 
 Cerebral hypoxia/anoxia  
 Central nervous system infection 
 Cerebral trauma 
 Postneurosurgery 
 Drug toxicity 
 Cerebral space occupying lesions 
 Venous sinus thrombosis 
 
Pathophysiology 
Status epilepticus is caused by a cerebral 
disturbance leading to a failure of 
mechanisms that would normally abort a 
single seizure, generally involving 
ineffective inhibition (transmission of δ-
aminobutyric acid (GABA)) or excessive 
excitation (glutamate transmission). While 
most neuronal damage can be attributed to 
systemic stresses (e.g. hyperpyrexia, 
hypoxia, hypoglycaemia), it is recognized 
that seizure activity is injurious to neurons. 
It is postulated that excessive glutamate 
release leads to intracellular calcium 
accumulation with subsequent neuronal 
dysfunction (excitotoxicity) and death. 
Certain neuronal populations, such as 
those of the hippocampus, are particularly 
vulnerable to seizure-induced neuronal 
damage and this is directly proportional to 
the duration and intensity of electrographic 
seizure activity. 
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The management of status epilepticus 
should be directed towards the following 
goals: 
 Immediate and continued stabilization 
of vital signs and cardio-respiratory 
function 
 Termination of seizure activity and 
preservation of neurons 
 Treatment of causes and precipitants 
 Prevention of medical complications 
 Prevention of seizure recurrence. 
 
The neurochemical basis of the abnormal 
discharge is not well understood. It may be 
associated with enhanced excitatory amino 
acid transmission, impaired inhibitory 
transmission or abnormal electrical properties 
of the affected cells. The glutamate content in 
areas surrounding an epileptic focus may be 
increased. Repeated epileptic discharge can 
cause neuronal death (excitotoxicity). Current 
drug therapy is effective in 70-80% of 
patients [14]. 
 
Epilepsy is the condition of spontaneously 
recurrent seizures. A seizure occurs when 
there is a sudden imbalance between the 
excitatory and inhibitory inputs to a network 
of neurons leading to hyperexcitability. 
Glutamate and Gamma.-amino butyric acid 
(GABA) are quantitatively the most 
important excitatory and inhibitory 
neurotransmitters, respectively, in the 
mammalian brain. Thus receptors of these 
two neurotransmitters are regarded as 
important targets for antiepileptic drugs. 
Despite the state-of-art medical treatment, 
drug-resistance remains a major clinical 
problem for one in three epileptic patients. 
Approximately 30% of patients with 
partial epilepsy and 25% of patients with 
generalized epilepsy are not controlled on 
medications. These patients often receive 
multiple medical treatments to control 
their seizures. Thus, there is an unmet need 
for new antiepileptic drug [20].
 
 
ANXIETY  
Anxiety is the classical word of our routine 
life. The concepts of anxiety may differ 
according to the individual’s state of 
contexts and interpretations. It is 
recognized that certain amount of anxiety 
is desirable, productive and can facilitates 
the individuals to grow but when the 
anxiety exceeds disturb the normal 
functions.It is estimated that about 25% of 
the population will experience an anxiety 
disorder at some stage of their life. 
Women are twice more likely to suffer 
from an anxiety disorders than men. 
Unfortunately, only 50% of people receive 
treatment for their disorder. Anxiety 
problem often leads to mental disorders. 
People with anxietydisorders are also at 
higher risk of being affected by substance 
abuse. So symptoms of severe, chronic, 
debilitating anxiety need treatment with an 
anti-anxiety agent [21, 22]. 
 
Anxiety is an unpleasant state of state of 
tension with an anticipation of imminent 
danger. Acute anxiety is generally 
transient but may reappear with 
appropriate stimuli. Somatic 
manifestations of anxiety include fatigue, 
dizziness, palpitation and excessive 
perspiration.  Anxiety is associated with 
almost all emotional disorders and 
frequently with physical illnesses [23]. 
 
A most important clinical generalization is 
that anxiety is rather infrequently a ‘disease’ 
in itself. Anxiety is completely associated 
with former psychoneurotic disorders. No 
psychological and biological explaination is 
involved easily. In addition symptoms of 
anxiety commonly are associated with 
depression and especially with dysthymic 
disorder (chronic depression of moderate 
severity), panic disorder, agora-phobia and 
other specific phobias, obsessive- compulsive 
disorders, eating disorders and many 
personality disorders [16].
 
 
Nature of Anxiety: [14] 
The normal ‘fear response’ to threatening 
stimuli comprises several components, 
including defensive behaviours, autonomic 
reflexes, arousal and a lertness, 
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corticosteroid secretion and negative 
emotions. In ‘anxiety state’, these 
reactions occur in an anticipatory manner, 
independently of external events. 10 % 
population of most developed countries 
uses anxiolytic drugs among the most 
frequent prescriptions. 
 
Anxiety disorders as recognized 
clinically include: 
 Generalized anxiety disorder: An 
ongoing state of excessive anxiety 
lacking any clear reason or focus. 
 Panic disorder: Attacks of 
overwhelming fear occurring in 
association with marked somatic 
symptoms such as sweating, 
tachycardia, chest pains, trembling, 
choking, etc. 
 Phobias: Strong fears of specific 
things or situations such as snakes, 
open spaces, flying, social interactions. 
 Post-traumatic stress disorder: 
Anxiety triggered by insistent recall of                               
past stressful experiences. 
 
GAMMA- AMINOBUTYRIC ACID 
(GABA) 
The major inhibitory nerotransmitter in the 
CNS is GABA (Gamma-amino butyric 
acid: NH2CH2CH2CH2COOH). Its 
presence in the brain first was reported in 
1950.
24 
l-Glutamic acid (glutamate) is the major 
neurotransmitter for fast excitatory 
synaptic transmission, whereas Gamma-
aminobutyricacid (GABA) is the major 
neurotransmitter for fast inhibitory 
synaptic transmission. Because of the 
widespread presence and utilization of 
glutamate and GABA as transmitters, one 
could say that they are involved in all 
functions of the central nervous system 
(CNS), as well as in all diseases. All the 
CNS drugs i.e., anti-anxiety, 
anticonvulsants, sedative-hypnotics and 
general anaesthetics act on GABA. Since 
its discovery in the CNS in the early 
1950s, GABA was shown to fulfill the 
criteria for establishment as a 
neurotransmitter [25].
 
 
Basic neurophysiology of GABA [26]:
 
When the presynaptic GABAergic neuron 
is depolarized, GABAis released from 
vesicles to the synaptic cleft by 
exocytosis.The transmitter molecules cross 
the cleft by passive diffusion and are bound 
to receptors on the postsynapticneuron. The 
most important postsynaptic GABA receptor 
is the GABAA-receptor, an ionotropic 
receptor where the GABA bindingsites are 
located on the alpha subunits. When GABA 
is bound to the receptor, Cl- ions flow into the 
cell, and the postsynaptic membrane 
ishyperpolarized. The GABAA receptor is a 
target fora number of pharmacological 
agents, for example benzodiazepinesand 
various anesthetics. Auto regulation of 
GABAergic neurons is mainly mediated 
through metabotropic GABAB receptors in 
the presynaptic cell membrane. 
 
 
Figure 5: General mechanism of GABAA receptor. 
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The effect of GABA is rapidly terminated 
by reuptakeof the transmitter into the 
presynaptic neuron and to a lesser degree 
uptake by surrounding astrocytes via 
GABA transporters (GAT). Four subtypes 
of transporters have so far been identified; 
GAT-1, primarily present on GABAergic 
neurons and to a lesser extent in astrocyte 
membranes, GAT-2, GAT-3 and the low 
affinity subtype BGT-1. The antiepileptic 
agent like tiagabine inhibits GAT-1 and 
thus increases the GABA concentration in 
the synaptic cleft, making more GABA 
available to the receptors. GABA taken up 
in the nerve terminal can be stored in 
vesicles and used again. Another option 
for intracellular GABA is conversion via 
GABA aminotransferase (GABA-T) to 
succinic semialdehyde, which is 
subsequently oxidized to succinate in 
theGABA shunt. 
 
Succinate formed from GABA can be 
utilized for energy production or formation 
of intermediate metabolites in the TCA 
cycle, for example α-ketoglutarate which 
can be converted to glutamate and 
glutamine (the latter only in as`trocytes). 
Glutamine can be transferred from the 
astrocyte back to the neuron, where it can 
be converted to glutamate in the 
mitochondria via the enzyme PAG. 
Glutamate can also be converted to α-
ketoglutarate and thus enter the TCA cycle 
of the neuron or be transformed into 
GABA again by the enzyme GAD. Figure 
7 shows the GABA recycling and its 
involvement of both neurons and 
astrocytes. 
 
Function [24]: 
GABA increases the permeability of 
membrane to specific ions in such a way 
as to cause the membranes to resist 
depolarization. By acting on GABAA 
receptor, GABA produces an increase in 
permeability to Cl
-
 ions that is measured as 
an increase in membraneconductance. 
GABA also produces increase in K
+
 
conductanceby action onGABABreceptor. 
 
 
Figure 6: Formation of GABA in neurons from glutamate. 
 
GABA is inactivated at synapses by a 
mechanism that involves attachment to 
unique membrane recognition sites, 
different from those for the receptor and 
subsequent removal from the synaptic 
junction by a Na
+
 and Cl
-
 dependent 
transport process that is similar in 
principle to that used for transport of many 
other substances. 
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GABA receptors [27, 28] 
Three distinct types of GABA receptors 
are characterized as follows: 
 
GABAA receptor 
Prevalent in mammalian brain is a ligand-
gated Cl
-
 ion channel that is opened after 
release of GABA from presynaptic 
neurons. It is responsible for the inhibitory 
neurotransmission in the CNS. This 
receptor has three basic binding sites; i) 
GABA site (b subunit), ii) Benzodiazepine 
site (a subunit) and iii) Barbiturate site. 
GABA binds to b subunit. 
Benzodiazepines and barbiturates bind to a 
subunit and to barbiturate site respectively, 
enhancing the GABA-induced ionic 
currents through these channels, i.e., they 
modulate the effects of GABA. 
 
 
Figure 7: GABAA receptor. 
 
GABAB receptor 
It is present in high concentration in the 
interpenduncular nuclei and cerebellum. It 
is an G-protein coupled receptor (GPCR) 
coupled both to biochemical pathways and 
to regulation of ion channels, a class of 
receptor referred to as metabotropic. 
 
GABAC receptor 
GABAC receptoris widely distributed in 
the CNS and most prominently in retinal 
neurons. It belongs to ligand gated ion 
channel family. 
 
The GABAA receptor is a chloride channel 
regulated by GABA binding, and it is now 
grouped in the superfamily of ligand-gated 
ion channel receptors. Increasing chloride 
permeability can depolarize the membrane 
potential. This depolarization could be 
sufficient to fire the cell, and it would be 
likely to activate certain voltage-gated ion 
channels, including calcium, that can, in 
turn, regulate other cellular events. The 
coupling mechanism depends on the cell 
location, because several G-protein– 
coupled effectors can be used, involving 
negative modulation of adenylate kinase 
and negative modulation of inositol tris 
phosphate production. These lead to 
activation of potassium channels or 
inhibition of voltage-gated calcium 
channels [25]. 
 
In the conventional view, GABA acts at 
either ionotropic GABAA or metabotropic 
GABAB receptors. Recently, novel 
ionotropic GABA receptors that are 
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composed of r-subunits have been 
identified in the vertebrate retina [25]. 
 
SPONTANEOUS MOTOR ACTIVITY 
(LOCOMOTOR ACTIVITY) [29,30]
 
A survey on methods to evaluate 
depressants of the central nervous system 
has been published by Turner (1965). 
Many of these tests are still valid in spite 
of the fact that new classes of drugs have 
been introduced since that time which 
have not only augmented the therapeutic 
armamentarium but also changed the 
battery of pharmacological tests. Mice and 
rats are used to test the CNS properties of 
drugs. Their spontaneous motor activity 
depends on various factors, such as the 
social situation (one ormore animals), 
familiarity with the test environment, light 
and temperature. The term spontaneous 
motoractivity includes different types of 
movements, such as locomotion, rearing, 
sniffing, grooming, eating anddrinking. 
These phenomena can be well recognized 
by a skilled observer, but are difficult to 
record overlong periods of time and to 
quantitate. Therefore, besides procedures 
based on observation many methods for 
automatic registrations have been 
developed. Almost every pharmacologist 
working in this field has designed his/her 
own apparatus. 
 
Most of the CNS acting drugs influence 
the locomotor activities in man and 
animals. The CNS depressant drugs reduce 
the motor activity while the stimulants 
increase the activity. The locomotor 
activity indicates alertness of mental 
activity. 
 
SKELETAL MUSCLE RELAXATION 
Muscle are engines which, like the steam 
engine and the internal combustion engine, 
use energy stored in chemical fuel to 
generate mechanical movement. 
Historically, the biological behavior of the 
heart in response to neurologic, 
biochemical, metabolic, pharmacologic or 
electrical stimuli has been related to its 
mechanical activity. Similarly, action 
potential has been related to mechanical 
contraction of skeletal muscle and resting 
potentials to mechanical muscle 
relaxation.
31
 
 
One of the important pharmacological 
actions of antianxiety agents of   
benzodiazepine class is muscle relaxing 
property. The skeletal muscle relaxation 
together with taming or calming effect also 
reduces anxiety and tension. The loss of 
muscle grip is an indication of muscle 
relaxation [30]. 
 
Many diseases of the brain and spinal cord 
produce an increase in muscle tone, which 
can be painful and disabling. Spasticity, 
resulting from birth injury or cerebral 
vascular disease and the paralysis 
produced by spinal cord lesions are 
examples. Local injury or inflammation, as 
in arthritis, can have the same effects and 
chronic back pain is also often associated 
with local muscle spasm [14]. 
 
Drugs acting as effective muscle relaxants 
are desirable in a wide variety of 
conditions. Thus, skeletal muscle relaxants 
able to reduce unwanted spasm or 
spasticity without interfering with 
consciousness and normal voluntary 
movements may find an important 
application in various neurological or 
musculo-skeletal disorders. Such drugs 
would also be valuable to surgeons during 
operative procedures, for achieving 
satisfactory muscle relaxation [32]. 
 
Decreased intracellular Ca
2+
concentration 
and increased MLC phosphatase activity is 
termed as relaxation. Ca
2+
 uptakeinto the 
sarcoplasmic reticulum is dependent on 
ATP hydrolysis. The plasma membrane 
also contains Ca, Mg-ATPases, providing 
anadditional mechanism for reducing the 
concentration of activatorCa
2+
 in the cell. 
Na
+
/Ca
2+
 exchangers are also located on 
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the plasma membraneand aid in decreasing 
intracellular Ca
2+
.
33 
 
PAIN 
Pain is the sensation that usually 
ariseswhen an agent causes real or 
potential damage toa bodily tissue. Such 
an agent is thus called a noxious stimulus, 
and the neural encoding and further 
processing of these stimuli is called 
nociception.Information on pain 
mechanisms is becoming increasingly 
available. For diagnosis, an effort should 
be made to characterize the symptom 
`pain' in a patient beyond the simple 
statement that the patient experiences pain. 
The aim is to define this symptom so that 
the neuronal mechanism possibly 
underlying the pain is taken into account. 
In recent years pain researchers have 
proposed classifying pain in terms of the 
pathophysiological mechanisms involved. 
Thus the focus is more on the mechanism 
than on the precise aetiology of the pain 
[34].
 
 
Anatomy of the Pain Pathway: [34] 
The ascending information of pain 
experience also accesses neurons of the 
rostral ventral medulla and midbrain 
periaqueductal gray to engage descending 
feedback systems that regulate the output 
from the spinal cord.
 
 
Figure 8: Anatomy of the Pain Pathway. 
 
Primary afferent neurones synthesize the 
excitatory neurotransmitter glutamate, 
aswell as neuropeptides such as substance 
P and calcitonin gene-related peptide 
(CGRP).Substance P and CGRP are 
transported from the neuronal soma along 
the neuronalprocesses into both the 
peripheral and the central endings. At the 
peripheral sensoryendings, substance P 
and CGRP can be released and produce a 
so-called neurogenicinflammation,thus 
participating in the phenomenon that leads 
to the excitation ofthese endings. When the 
action potentials thus elicited arrive at the 
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central endings, substance P and CGRP are 
released here together with glutamate. 
Many second-order neurons inthespinal 
cord have long axons that form tracts 
ascending to the thalamus and brain-
stem.for the transmission of nociceptive 
information to the brain, the spin thalamic 
tracts are the most important. Other 
second-order neurones are involved in 
motor reflex and autonomic pathways 
[35]. 
 
Pain is an ill defined sensation, protective 
and indicative in nature, usually appear by 
internal or external noxious stimulus. Pain 
is a warning signal and primarily 
protective nature, but causes discomfort. 
Excessive pain may be unbearable and 
cause other effects – sinking sensation, 
apprehension, sweating, nausea, 
palpitation and rise or fall in B.P, 
tachypnea [36].
 
Bradykinin, released from plasma 
kininogen and cytokines such as TNFα, 
IL-1 & IL – 8, appear to be particularly 
important in eliciting the pain of 
inflammation (releases prostaglandins and 
other mediators). Neuropeptides, such as 
substance-P and calcitonin gene related 
peptide, also may be involved in eliciting 
pain [16].
 
 
Pain consists of two components: 
1. Original sensation (Perception 
Component): The original sensation 
that travels over the pain pathways is 
presumably the same for everyone and 
depends on the intensity of the 
stimulus. 
2. Psychologic modification of original 
sensation (Reaction component): In 
this case the reaction is not the same 
for any two people and not identical 
for one person on different occasions. 
It depends on factors like past 
experience, conditioning, memory and 
judgment. 
 
Generally pain is classified into two 
types: 
1. Acute pain: It is temporary, having an 
instantaneous onset, eventually 
subsiding by treatment or on its own 
accord. eg: renal colic and headache. 
2. Chronic pain: It is continuous and 
gradual in onset, so that the exact time 
of onset is uncertain. It is refractory to 
treatment. Eg: rheumatoid arthritis and 
pain of malignancy. 
 The evidences indicate that production 
of bradykinin and prostaglandins are 
associated with pain. The other pain 
producing substances can be grouped 
as follows: 
 Acetylcholine and lactic acid. 
 Kinins or kinin liberating substance.  
 Phospholipase which splits lysolecithin 
from phospholipids, lysolecithin 
causes histamine release from the 
tissues, and it disrupts mast cells, 
which liberates 5-hydroxytryptamine. 
 Proteolytic enzymes and non-protein 
toxins causes breakdown of tissues 
liberating potassium from muscles and 
bradykinin from plasma etc. whereas 
heamolysins affect only blood cells, 
causing haemolysis and the liberation 
of potassium [23].
 
 
Pain pathways 
Pain may be in two states: 
1. The peripheral nociceptive afferent 
neuron, which is activated by noxious 
stimuli. 
2. The central mechanism by which the 
afferent input generates a pain 
sensation.
14
 
 
It appears that tactile sensation is 
transmitted by large diameter (L), fast 
conducting nerve fibres and pain via small 
diameter (S), slow conducting nerve fibres. 
Such an impulse on reaching the spinal 
cord activates the first transmission cell 
and the collateral cell in the substantia 
gelatinosa (SG). Anatomically, these nerve 
fibres are carried in the dorsal nerve roots 
and end in the substantia gelatinosaat the 
apex of the dorsal gray horn and in the 
intermediate gray matter in the spinal cord. 
The substantia gelatinosa cells inhibit the 
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passage of signals and thus decrease the 
output reaching the higher centres. If 
however, pain stimulus is more intense, 
then the substantia gelatinosa cells are 
inhibited, releasing in higher output 
reaching the higher centres, leading to 
perception of pain. Thus, this gate control 
allows the sensory input to be decreased or 
augmented depending on the relative 
activity of large diameter L fibres and 
small diameter S fibres. 
 
 The secondary axons which arise from the 
dorsal horn cross over to the side around 
the central canal of the spinal cord and 
form the spinothalamic tract. The 
intermediate gray matter gives origin to 
the spinoreticular fibres which intermingle 
with the spinothalamic tract. The 
spinothalamic pathway terminates in the 
thalamus and the post central gyrus which 
is mainly responsible for localization of 
pain sensation.  
 
Although the thalamus is responsible for 
perception of pain, the cerebral cortex is 
essential for its discriminative, exact and 
meaningful interpretation and for some of 
its emotional components. The other 
intermingled fibres which form an 
ascending multisynaptic pathway 
terminate in the thalamus and from there 
project tofrontal and limbic systems, and 
the hypothalamus. This system is 
concerned with the emotional 
concomitants of pain. 
 
Higher centres through their central 
inhibitory and facilitary mechanisms exert 
modulating influence on the gate 
mechanism. Thus, clinically the sensation 
of pain has several components including 
the emotional reaction [29]. 
 
 
CONCLUSION 
Neuropharmacology has remain a very 
vast and deep research area for the primary 
care individuals, doctors, surgeons, 
pharma professionals and the scientists 
form the ancient times. The main issue 
behind the sign and symptoms of the neuro 
pharmacology is the exact recognition of 
the patient or the individuals having 
trouble with neuro disorders. Until the 
prime reason of CNS defects is unclear an 
appropriate therapy to the illness is not 
possible. So here we did try to get a few 
reasons and underlying mechanisms 
(Based on General Considerations) and 
found that the underlying mechanisms, 
pathogenesis and the entire reasons of the 
CNS defects should be known and clear 
for the effective treatment to neuro 
patients/individuals.
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